Guinea-Bissau's Planned US-Funded Baby Vaccine Trial Blasted by WHO
The World Health Organization (WHO) has criticized a US-funded hepatitis B vaccine trial in Guinea-Bissau as "unethical," halting a plan to vaccinate newborns. The study aimed to compare the effects of administering the vaccine at birth versus six weeks of age. The WHO expressed concerns about the trial's scientific justification, ethical safeguards, and adherence to established research standards, despite the vaccine's proven effectiveness and safety record.
The US health department, led by Robert F. Kennedy Jr., who has questioned vaccine safety, sought to use the trial to explore broader health implications. However, the WHO emphasized that the vaccine has been safely used for over three decades in over 115 countries. They argue that giving the vaccine to some newborns but not others could lead to "potentially irreversible harm."
Guinea-Bissau's significant hepatitis B prevalence, affecting an estimated portion of its population, makes vaccination crucial. The WHO recommends birth vaccination to prevent mother-to-baby transmission in 70-95% of cases. They argue that trials using placebos or withholding treatment are only acceptable when no proven treatment exists, which is not the case with the hepatitis B birth dose vaccine.
The trial, involving 14,000 babies, was suspended due to public outrage. Critics, including Guinea-Bissau's former health minister, Magda Robalo, questioned the necessity of the trial. The WHO's stance highlights the importance of ethical considerations in medical research, especially when a proven, life-saving intervention is available.
